Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers
Tóm tắt
The pharmacokinetics of immediate (IR) and modified release (MR) trimetazidine (TMZ) in dogs and pigs, have been compared under single dose conditions, then predicted at steady-state under conditions mimicking an actual human pharmacokinetics study. In both animal species, the MR tablet has demonstrated sustained release properties, as assessed by delayed time to peak and increased mean absorption times. Multiple dose simulations in dogs revealed a delayed time to peak (3.0 vs. 1.0 h), a decrease in peak plasma concentration (544 vs. 659 μg/L), an increase in trough concentrations (115 vs. 63 μg/L), a decrease in peak-trough fluctuation (141 vs. 193 %), and an increase in plateau time (5.5 vs. 4.9 h). Qualitatively similar changes were simulated in pigs. These properties have then been verified in humans where a TMZ MR 35 mg b.i.d regimen did provide similar total exposure, increased plateau time (11 vs. 4 h), decreased peak-trough fluctuation (86 vs. 121%), a 31% increase in trough concentrations, and no increase in inter-individual variability as compared to a TMZ IR 20 mg t.i.d. regimen. Furthermore, the TMZ MR 35 mg b.i.d. regimen is likely to result in improved patient compliance and better patient anti-ischemic protection in the early morning.
Tài liệu tham khảo
Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. (1994): Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. Clin. Pharmacol., 37, 279–288.
Szwed H., Sadowski Z., Elikowski W., Koronkiewicz A., Mamcarz A., Orszulak W., Skibinska E., Szymczak K., Swiatek J., Winter M. (2001): Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart. J., 22, 2267–2274.
Manchanda S.C., Krishnaswami S. (1997): Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart, 78, 353–357.
Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. (2000): The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res., 86, 580–588.
CPMP/EWP/280/96 (1999): Note for guidance on modified release oral and transdermal dosage forms: Section II (Pharmacokinetic and clinical evaluation). Adopted by EMEA (European Agency for Evaluation of Medicinal Products). London.
Mulcahy D. (1999): “Circadian” variation in cardiovascular events and implications for therapy. J. Cardiovasc. Pharmacol., S34, 3–8.
Sellier P., Broustet J.P. (2003): Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs, 3, 361–369.